iOnctura Appoints Industry Veteran Dr. Joanna Horobin as Chair
Geneva, Switzerland, 27 May 2010: iOnctura SA, a clinical stage biopharmaceutical company, developing … Continue reading “iOnctura Appoints Industry Veteran Dr. Joanna Horobin as Chair”
Geneva, Switzerland, 27 May 2010: iOnctura SA, a clinical stage biopharmaceutical company, developing … Continue reading “iOnctura Appoints Industry Veteran Dr. Joanna Horobin as Chair”
BaseLaunch, the Basel Area-based incubator and accelerator that helps scientists and entrepreneurs … Continue reading “Roche becomes founding partner of BaseLaunch Phase II”
Acesion Pharma, a Danish pharmaceutical company developing novel treatments for atrial fibrillation … Continue reading “Acesion Pharma Strengthens Clinical Team with Key Appointments”
First calcium matrix to receive European approval as an antibiotic carrier for … Continue reading “Biocomposites announces new CE Mark for STIMULAN®”
Seasoned Biotech Executive Colin Goddard Joins as Executive Chairman Basel, Switzerland, 22 … Continue reading “FoRx Therapeutics AG Raises EUR 10 Million Seed Round First Company to Develop a Pipeline of Drugs Targeting DNA Replication Stress for Cancer”
20 April 2020, Cambridge, UK: STORM Therapeutics, the biotechnology company focused on … Continue reading “STORM Therapeutics appoints Dr. Angus Lauder as Director of Business Development”
17 April 2020, Cambridge, UK: STORM Therapeutics, the biotechnology company focused on … Continue reading “STORM Therapeutics announces publication in Nature Reviews Cancer on the role of RNA Modifications in Cancer by Founder Professor Tony Kouzarides”
LONDON, 15 April 2020: Arix Bioscience plc (LSE: ARIX) (“Arix” or the … Continue reading “Jonathan Tobin, PhD, promoted to Managing Director, Arix Bioscience”
Targeting reconstruction, spine, trauma and foot and ankle Keele, UK, 15 April … Continue reading “Biocomposites Appoints President”
London UK, April 14, 2020 – Today Ori Biotech Ltd (Ori) an … Continue reading “Ori Biotech partners with Achilles Therapeutics to test novel cell therapy manufacturing platform”
IXICO plc (AIM: IXI) is pleased to announce today the signing of … Continue reading “£10.5m contract win, trading update for the period ended 31 March 2020, and the potential impact of COVID-19”
Los Angeles, USA and Vancouver, Canada, April 7, 2020 – ImaginAb Inc., … Continue reading “ImaginAb and ARTMS Announce Strategic Partnership for Innovative Manufacture of 89Zr CD8 ImmunoPET Agent”
Strengthens management team as Gadeta receives approval to start first clinical study … Continue reading “Gadeta appoints Marco Londei as Chief Executive Officer”
Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that Dr. Richard Philipson has … Continue reading “Calliditas appoints new Chief Medical Officer”
New help desks in Spain and Italy offering psychological support during COVID-19 … Continue reading “Neuraxpharm launches the social initiative “Quarantine Together” to provide psychological support to families in Spain and Italy during COVID-19”
Business collaboration signed with Panaxia Labs, Israel’s largest cannabis manufacturer, to market … Continue reading “Neuraxpharm enters the advanced medical cannabis market in Germany with a collaboration with Panaxia”
Calliditas Therapeutics AB (publ) (“Calliditas”) today announced it has strengthened its operations … Continue reading “Calliditas strengthens its US Commercial Organization”
Los Angeles, CA, USA, March 30, 2020 – ImaginAb Inc., a leading … Continue reading “ImaginAb Announces Licensing Deal with AstraZeneca for CD8 ImmunoPET Technology”
Extension to in-use stability time FARNBOROUGH, England, [23] March, 2020: Flexipharm Austrading, … Continue reading “Flexipharm Austrading announces product update on Arsenic Trioxide Phebra”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2020 Optimum Strategic Communications All rights reserved.
Warnford Court
29 Throgmorton Street
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com